Metabolic syndrome-related hepatocellular carcinoma treated by volumetric modulated arc therapy

Jonathan H. Klein, L. A. Dawson, T. H. Tran, O. Adeyi, T. Purdie, M. Sherman, A. Brade

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality, and its incidence is increasing in developed countries. Risk factors include cirrhosis from viral hepatitis or alcohol abuse. Metabolic syndrome is a newly recognized, but important, risk factor that is likely contributing to the increased incidence of HCC. Surgery is the therapy of choice for HCC, but local therapies are often contraindicated, usually because of advanced disease or comorbid conditions such as cardiac disease (which is associated with metabolic syndrome). Current radiation therapy techniques such as stereotactic body radiotherapy allow for treatment plans that highly conform to the target and provide excellent sparing of normal structures. Radiation therapy is emerging as a viable option in patients not eligible for surgery or other locoregional therapies. Here, we report a case of a large hcc presenting in a patient with metabolic syndrome without significant alcohol history or biochemical liver dysfunction. The patient was not a candidate for locoregional therapies because of cardiac and renal comorbidities typical of patients experiencing the long-term sequelae of metabolic syndrome. Treatment using an arc-based volumetric-modulated arc therapy technique allowed for the highest dose of radiation to be delivered to the tumour while the peripheral radiation dose was minimized. A complete local response was confirmed by computed tomography imaging 21 months after treatment completion.

Original languageEnglish (US)
JournalCurrent Oncology
Volume21
Issue number2
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Intensity-Modulated Radiotherapy
Hepatocellular Carcinoma
Therapeutics
Radiotherapy
Radiation
Radiosurgery
Incidence
Developed Countries
Hepatitis
Alcoholism
Comorbidity
Liver Diseases
Heart Diseases
Neoplasms
Fibrosis
History
Tomography
Alcohols
Kidney
Mortality

Keywords

  • Hepatocellular carcinoma
  • IMRT
  • Liver cancer
  • Metabolic syndrome
  • Radiotherapy
  • SBRT
  • VMAT

ASJC Scopus subject areas

  • Oncology

Cite this

Metabolic syndrome-related hepatocellular carcinoma treated by volumetric modulated arc therapy. / Klein, Jonathan H.; Dawson, L. A.; Tran, T. H.; Adeyi, O.; Purdie, T.; Sherman, M.; Brade, A.

In: Current Oncology, Vol. 21, No. 2, 01.01.2014.

Research output: Contribution to journalArticle

Klein, Jonathan H. ; Dawson, L. A. ; Tran, T. H. ; Adeyi, O. ; Purdie, T. ; Sherman, M. ; Brade, A. / Metabolic syndrome-related hepatocellular carcinoma treated by volumetric modulated arc therapy. In: Current Oncology. 2014 ; Vol. 21, No. 2.
@article{ed7555e7c9a340878494966a6eb5da21,
title = "Metabolic syndrome-related hepatocellular carcinoma treated by volumetric modulated arc therapy",
abstract = "Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality, and its incidence is increasing in developed countries. Risk factors include cirrhosis from viral hepatitis or alcohol abuse. Metabolic syndrome is a newly recognized, but important, risk factor that is likely contributing to the increased incidence of HCC. Surgery is the therapy of choice for HCC, but local therapies are often contraindicated, usually because of advanced disease or comorbid conditions such as cardiac disease (which is associated with metabolic syndrome). Current radiation therapy techniques such as stereotactic body radiotherapy allow for treatment plans that highly conform to the target and provide excellent sparing of normal structures. Radiation therapy is emerging as a viable option in patients not eligible for surgery or other locoregional therapies. Here, we report a case of a large hcc presenting in a patient with metabolic syndrome without significant alcohol history or biochemical liver dysfunction. The patient was not a candidate for locoregional therapies because of cardiac and renal comorbidities typical of patients experiencing the long-term sequelae of metabolic syndrome. Treatment using an arc-based volumetric-modulated arc therapy technique allowed for the highest dose of radiation to be delivered to the tumour while the peripheral radiation dose was minimized. A complete local response was confirmed by computed tomography imaging 21 months after treatment completion.",
keywords = "Hepatocellular carcinoma, IMRT, Liver cancer, Metabolic syndrome, Radiotherapy, SBRT, VMAT",
author = "Klein, {Jonathan H.} and Dawson, {L. A.} and Tran, {T. H.} and O. Adeyi and T. Purdie and M. Sherman and A. Brade",
year = "2014",
month = "1",
day = "1",
doi = "10.3747/co.21.1756",
language = "English (US)",
volume = "21",
journal = "Current Oncology",
issn = "1198-0052",
publisher = "Multimed Inc.",
number = "2",

}

TY - JOUR

T1 - Metabolic syndrome-related hepatocellular carcinoma treated by volumetric modulated arc therapy

AU - Klein, Jonathan H.

AU - Dawson, L. A.

AU - Tran, T. H.

AU - Adeyi, O.

AU - Purdie, T.

AU - Sherman, M.

AU - Brade, A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality, and its incidence is increasing in developed countries. Risk factors include cirrhosis from viral hepatitis or alcohol abuse. Metabolic syndrome is a newly recognized, but important, risk factor that is likely contributing to the increased incidence of HCC. Surgery is the therapy of choice for HCC, but local therapies are often contraindicated, usually because of advanced disease or comorbid conditions such as cardiac disease (which is associated with metabolic syndrome). Current radiation therapy techniques such as stereotactic body radiotherapy allow for treatment plans that highly conform to the target and provide excellent sparing of normal structures. Radiation therapy is emerging as a viable option in patients not eligible for surgery or other locoregional therapies. Here, we report a case of a large hcc presenting in a patient with metabolic syndrome without significant alcohol history or biochemical liver dysfunction. The patient was not a candidate for locoregional therapies because of cardiac and renal comorbidities typical of patients experiencing the long-term sequelae of metabolic syndrome. Treatment using an arc-based volumetric-modulated arc therapy technique allowed for the highest dose of radiation to be delivered to the tumour while the peripheral radiation dose was minimized. A complete local response was confirmed by computed tomography imaging 21 months after treatment completion.

AB - Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality, and its incidence is increasing in developed countries. Risk factors include cirrhosis from viral hepatitis or alcohol abuse. Metabolic syndrome is a newly recognized, but important, risk factor that is likely contributing to the increased incidence of HCC. Surgery is the therapy of choice for HCC, but local therapies are often contraindicated, usually because of advanced disease or comorbid conditions such as cardiac disease (which is associated with metabolic syndrome). Current radiation therapy techniques such as stereotactic body radiotherapy allow for treatment plans that highly conform to the target and provide excellent sparing of normal structures. Radiation therapy is emerging as a viable option in patients not eligible for surgery or other locoregional therapies. Here, we report a case of a large hcc presenting in a patient with metabolic syndrome without significant alcohol history or biochemical liver dysfunction. The patient was not a candidate for locoregional therapies because of cardiac and renal comorbidities typical of patients experiencing the long-term sequelae of metabolic syndrome. Treatment using an arc-based volumetric-modulated arc therapy technique allowed for the highest dose of radiation to be delivered to the tumour while the peripheral radiation dose was minimized. A complete local response was confirmed by computed tomography imaging 21 months after treatment completion.

KW - Hepatocellular carcinoma

KW - IMRT

KW - Liver cancer

KW - Metabolic syndrome

KW - Radiotherapy

KW - SBRT

KW - VMAT

UR - http://www.scopus.com/inward/record.url?scp=84898778077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898778077&partnerID=8YFLogxK

U2 - 10.3747/co.21.1756

DO - 10.3747/co.21.1756

M3 - Article

AN - SCOPUS:84898778077

VL - 21

JO - Current Oncology

JF - Current Oncology

SN - 1198-0052

IS - 2

ER -